Entheon Biomedical Corp. has announced the submission of the regulatory package for its upcoming Phase 1 Clinical trial, EBRX-101, to the ethics committee of the BEBO Foundation for the Assessment of Ethics of Biomedical Research (the "Ethics Committee"). The Ethics Committee is an independent Medical Research Ethics Committee for biomedical scientific research involving human subjects taking place within the Netherlands.

Concurrent to the review of the regulatory package, site initiation and initial screening is planned for the near-term, with patient recruitment and enrollment to follow shortly thereafter. EBRX-101 is the primary research focus of Entheon RXTM, one of Entheon's core business divisions, which is advancing the therapeutic potential of N, N-dimethyltryptamine (DMT) and next-generation DMT- based drug analogues. The study will evaluate the pharmacodynamics, pharmacokinetics and safety of a target controlled intravenous infusion of DMT in a population of otherwise healthy smokers.